Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance

NCT01199731 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01199731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01199731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Terminated
Start date
October 5, 2010
Completion date
July 19, 2011
Enrollment
30 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus